Abstract
The following study evaluated effects of PPAR-agonists on cardio-renal parameters in Sprague-Dawley rats. Animals were instrumented with telemetry for hemodynamic evaluation and subjected to serial echocardiography. Animals were randomized (4 groups) and treated for 28 days (n=10/group): vehicle (VEH), PD0344168 (PD168-10 or 50 mg/kg, PPAR-α/γ co-agonist) or rosiglitazone (RGZ 80 mg/kg, PPAR-γ agonist). Urinary sodium was markedly decreased with PD168-10 and 50 (20% and 31%, respectively) but not RGZ. VEH hematocrit (HCT %) did not change, whereas PD168-10 and 50 and RGZ decreased HCT % (13, 30 and 3 %, respectively). Compared to VEH, PD168-50 exhibited decreased systolic blood pressure (SBP) (118 vs. 105 mmHg) and elevated heart rate (HR) (357 vs. 370 bpm), whereas in animals with PD168-10 or RGZ, SBP and HR were not different from VEH. PD168-10 and 50 significantly decreased ejection fraction (10 and 16%, respectively) compared to VEH, whereas administration of RGZ had no impact. PD168-10 and 50 and RGZ significantly increased LV area in diastole (1.1, 1.2,1.0 vs. 0.89 cm2, respectively) compared to VEH. All treatments decreased serum glucose and increased adiponectin vs. VEH (5.1, 38.8, 60.7, 24.6 ng/mL; VEH, PD168-10, 50 and RGZ, respectively). These data demonstrate that administration of PPAR-agonists results in dose-dependent changes in cardio-renal function that may contribute to fluid retention.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
